Manchester United’s Diogo Dalot Invests Over €1M in Bioniq, Joining Cristiano Ronaldo

London, February 25, 2025 – Bioniq, founded in 2019 and renowned for its personalized nutritional supplements based on blood biomarker data, is proud to announce that football star Diogo Dalot, right-back for Manchester United and the Portugal national team, has joined the company as an investor, contributing over €1 million. Dalot joins the global football icon Cristiano Ronaldo, who became a major investor in 2024, and brought Bioniq’s total valuation to $82 million. Dalot’s investment marks another milestone in Bioniq’s mission to make personalized health accessible to athletes and everyday individuals worldwide.

"When it comes to high-level performance, my biggest focus has always been finding that extra 1% — the key to setting myself apart from the rest. Since discovering Bioniq in 2022, it’s been a game-changer for me. I've seen the results for myself. Achieving such progress is only possible with a product that’s truly personalized and tailored specifically to my needs,”said Diogo Dalot. “Now, I’m thrilled to take the next step as an investor. I believe in Bioniq’s mission and see the tremendous potential of this business, especially with the growing global demand for personalized nutrition."Diogo Dalot, a dedicated Bioniq member for over four years, has integrated the Bioniq formula into his daily routine to optimize health and performance. His commitment extends to active collaboration with the Bioniq team on product innovation, contributing his insights as a professional athlete. With the launch of Bioniq’s hyper-personalized supplement, Build Your Own, Dalot has created an even more precise supplement routine, allowing him to vary his nutrient intake based on his performance goals. While the PRO formula is designed to reduce inflammation, increase resilience, and improve endurance, his adjunct Build Your Own allows mild inflammation as a natural part of the muscle-building process.

“Diogo has an exceptional approach to performance optimization and recovery, constantly seeking the most effective and scientifically backed methods to enhance his physical and cognitive capabilities,” said Vadim Fedotov, Founder and CEO of Bioniq. “His dedication to craft and commitment to maximizing potential makes him a perfect fit for Bioniq. He shares our vision and mission, recognizing that the future of health lies in precision, personalization, and efficacy. His investment is yet another testament to this shift — where science-driven, individualized solutions create meaningful impact in the industry and everyday well-being.”

Bioniq was developed by scientists to improve the physical and cognitive function of Olympic athletes. Today, products are available for customers from 70 countries, with its total user base growing more than 10x in 2024. Bioniq stands at the forefront of the rapidly expanding supplements market, which was valued at USD 177.50 billion in 2023 and is projected to grow at a CAGR of 9.1% from 2024 to 2030.

Dalot’s investment follows the 2024 investment by Cristiano Ronaldo, as well as a successful Series B round, which raised $15 million, led by Principal Investors HV Capital and Unbound, two leading European VCs. 

Bioniq’s ability to provide quantifiable before-and-after snapshots of users’ nutrient needs, proven effectiveness, and optimization progress has been an invaluable asset in its partnerships with many leading health and sports institutions such as Lanserhof and UFC. Bioniq has also become the product of choice for many other of the world's top athletes from Soccer World Cup Champions, NBA All-Stars to Iron Man winners.

About Bioniq
‍
Bioniq, launched in 2019 in London, UK, is the industry leader in offering AI-driven personalized supplements based on blood test data. After conducting years of testing, Bioniq has developed the largest of its kind proprietary biochemical database with blood test data from customers across 5 continents. Shipping globally, Bioniq has created unique formulas for over 300,000 users that incorporate components and dosages tailor-made to each individual’s nutrient deficiencies, as identified through their blood results.

Media Contact:

Vlada Lomova
[email protected]